Viktor Grünwald, MD, PhD
Articles
1L Treatment Landscape for Advanced Renal Cell Carcinoma
December 20th 2024Panelists discuss how the evolving first-line treatment landscape for advanced renal cell carcinoma is shaped by novel immunotherapy combinations, including lenvatinib plus pembrolizumab, and the impact of these therapies on patient outcomes and progression patterns.
Viktor Grünwald, MD, PhD, on CLEAR Trial Subgroup Analyses of Pembrolizumab/Lenvatinib in RCC
June 5th 2021CancerNetwork® sat down with Viktor Grünwald, MD, PhD, at the 2021 ASCO Annual Meeting to talk about how new data from the CLEAR trial serve to further inform clinicians about lenvatinib and pembrolizumab for first-line renal cell carcinoma.
Latest Updated Articles
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Published: May 17th 2013 | Updated: December 22nd 2024
Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
Published: December 1st 2016 | Updated: December 22nd 2024
Patient With History of COPD Presents With Abdominal Pain
